My biotech company, GenoMed (OTC Pink Sheets: GMED) has had encouraging results treating West Nile virus encephalitis since 2003: 81% treatment success rate in people (22 of 27), 75% in horses, and 50% in birds. Our first 8 WNV patients were published in a peer-reviewed medical journal in 2004. We’re eager to see if our approach works again this year. Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on our company’s homepage at www.genomed.com.
Dave Moskowitz MD
CEO & Chief Medical Officer
GenoMed, Inc. www.genomed.com
Comment Reply
My biotech company, GenoMed (OTC Pink Sheets: GMED) has had encouraging results treating West Nile virus encephalitis since 2003: 81% treatment success rate in people (22 of 27), 75% in horses, and 50% in birds. Our first 8 WNV patients were published in a peer-reviewed medical journal in 2004. We’re eager to see if our approach works again this year. Anybody who wants to download our WNV trial protocol can do so for free at any time by clicking on the "West Nile trial" link on our company’s homepage at www.genomed.com.
Dave Moskowitz MD
June 21, 2008 - 11:52amCEO & Chief Medical Officer
GenoMed, Inc.
www.genomed.com
This Comment
Reply